BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu J, Sun T, Zhang J, Liu Y, Wang D, Zhu H, Yao H, Ding J, Hu G, Lu M. Drd2 biased agonist prevents neurodegeneration against NLRP3 inflammasome in Parkinson’s disease model via a β-arrestin2-biased mechanism. Brain, Behavior, and Immunity 2020;90:259-71. [DOI: 10.1016/j.bbi.2020.08.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao F, Huang C, Cheng J, He Z. β-arrestin-2 alleviates rheumatoid arthritis injury by suppressing NLRP3 inflammasome activation and NF- κB pathway in macrophages. Bioengineered 2022;13:38-47. [PMID: 34787064 DOI: 10.1080/21655979.2021.2003678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Huang S, Chen Z, Fan B, Chen Y, Zhou L, Jiang B, Long H, Zhong W, Li X, Li Y. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease. J Neuroimmunol 2021;354:577543. [PMID: 33714750 DOI: 10.1016/j.jneuroim.2021.577543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yang Y, Song J, Liu N, Wei G, Liu S, Zhang S, Jiang N, Yang H, Du G. Salvianolic acid A relieves cognitive disorder after chronic cerebral ischemia: Involvement of Drd2/Cryab/NF-κB pathway. Pharmacol Res 2021;175:105989. [PMID: 34800628 DOI: 10.1016/j.phrs.2021.105989] [Reference Citation Analysis]
4 Wang C, Yang T, Liang M, Xie J, Song N. Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation. Transl Neurodegener 2021;10:39. [PMID: 34657636 DOI: 10.1186/s40035-021-00265-y] [Reference Citation Analysis]
5 Li M, Zhou L, Sun X, Yang Y, Zhang C, Wang T, Fu F. Dopamine, a co-regulatory component, bridges the central nervous system and the immune system. Biomed Pharmacother 2022;145:112458. [PMID: 34847478 DOI: 10.1016/j.biopha.2021.112458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Wang K, Lu C, Wang T, Qiao C, Lu L, Wu D, Lu M, Chen R, Fan L, Tang J. Hyperoside suppresses NLRP3 inflammasome in Parkinson's disease via Pituitary Adenylate Cyclase-Activating Polypeptide. Neurochem Int 2022;152:105254. [PMID: 34883151 DOI: 10.1016/j.neuint.2021.105254] [Reference Citation Analysis]
7 Feng YS, Tan ZX, Wu LY, Dong F, Zhang F. The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases. Biomed Pharmacother 2021;138:111428. [PMID: 33667787 DOI: 10.1016/j.biopha.2021.111428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]